Following after are RSV vaccines from Johnson & Johnson as well ... It will compete with Sobi's Synagis (palivizumab), an antibody originated by AZ, which is dosed once a month.

One dose of any of these three vaccines will complete your vaccination. The monoclonal antibodies palivizumab (Synagis) and nirsevimab (Beyfortus), are recommended for infants who are too young ...

As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...

Synagis is a former blockbuster – first approved ... However, revenues from the antibody are expected to drop sharply once Beyfortus and vaccines for RSV prevention enter the market.

A similar antibody treatment injection, called Synagis, has been available for infants at especially high-risk for RSV since 1998. You can get an RSV vaccine from your physician or local retail ...

A similar antibody treatment injection, called Synagis, has been available for infants at especially high-risk for RSV since 1998. You can get an RSV vaccine from your physician or local retail ...

Synagis is administered as a monthly injection during RSV ... Recent research advancements have introduced RSV vaccines and monoclonal antibodies that protect specific populations from serious ...

While Robert F. Kennedy Jr., President Donald Trump’s pick to lead the US Department of Health and Human Services, has backpedaled on his anti-vaccine rhetoric during his Senate confirmation ...

There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...

Kennedy Jr., has a long history of raising doubts about vaccines — despite decades of evidence showing they've saved millions of people from debilitating illness or death. "People forget what it ...

If he were to oversee government agencies like the CDC, NIH, and FDA, scientists fear that he could encourage states to weaken vaccination requirements. The controversial nomination—and the ...